K
Kenichi Miyata
Researcher at Takeda Pharmaceutical Company
Publications - 11
Citations - 260
Kenichi Miyata is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Nucleic acid & Ring (chemistry). The author has an hindex of 5, co-authored 11 publications receiving 154 citations.
Papers
More filters
Journal ArticleDOI
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles.
Tsukasa Sugo,Michiko Terada,Tatsuo Oikawa,Kenichi Miyata,Satoshi Nishimura,Kenjo Eriya,Mari Ogasawara-Shimizu,Yukimasa Makita,Sachiko Imaichi,Shumpei Murata,Kentaro Otake,Kuniko Kikuchi,Mika Teratani,Yasushi Masuda,Takayuki Kamei,Shuichi Takagahara,Shota Ikeda,Tetsuya Ohtaki,Hirokazu Matsumoto +18 more
TL;DR: A novel platform targeted to muscular organs by conjugation of siRNAs with anti-CD71 Fab' fragment shows durable gene-silencing in the heart and skeletal muscle for one month after intravenous administration in normal mice and demonstrates the utility of antibody conjugate for siRNA delivery and the therapeutic potential for muscular diseases.
Journal ArticleDOI
Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood–brain barrier and knock down genes in the rodent CNS
Tetsuya Nagata,Chrissa A. Dwyer,Kie Yoshida-Tanaka,Kensuke Ihara,Masaki Ohyagi,Hidetoshi Kaburagi,Haruka Miyata,Satoe Ebihara,Kotaro Yoshioka,Takashi Ishii,Kanjiro Miyata,Kenichi Miyata,Berit Powers,Tomoko Igari,Syunsuke Yamamoto,Naoto Arimura,Hideki Hirabayashi,Toshiki Uchihara,Rintaro Iwata Hara,Rintaro Iwata Hara,Takeshi Wada,C. Frank Bennett,Punit P. Seth,Frank Rigo,Takanori Yokota +24 more
TL;DR: In this article, DNA/RNA heteroduplex oligonucleotides conjugated to cholesterol or α-tocopherol at the 5′ end of the RNA strand reach the central nervous system (CNS) after subcutaneous or intravenous administration in mice and rats.
Patent
Aromatic amine derivative and use thereof
TL;DR: In this paper, the authors presented a novel SCD inhibitor with a compound represented by the formula [I] wherein ring A is an optionally substituted aromatic ring, ring B is a optionally substituted ring, R is a hydrogen atom, H is a heterocyclic group, and X is a spacer having 1 to 5 atoms in the main chain.
Patent
Spiro compound and use thereof
TL;DR: In this paper, the authors proposed a novel SCD inhibitor consisting of a compound represented by the formula (I) wherein I is an optionally substituted cyclic group or an optionally substituting carbamoyl group, provided that R is not an 8-pyrido[2,3-d]pyrimidyl group.
Patent
Antibody-drug conjugate
TL;DR: In this paper, an antibody-drug conjugate (ADC) was proposed for delivering the drug to a tissue or a cell of muscle or the like, and a composition comprising the conjugates was provided.